RecruitingGeneralized Myasthenia Gravis

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Eligible age

18–80 yrs

Accepts

All genders

Locations

25 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Sponsor: Immunovant Sciences GmbH

You may qualify if…

✓ Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.
✓ Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit
✓ Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1)
✓ Additional inclusion criteria are defined in the protocol.

You may not qualify if…

✕ Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit.
✕ Have had a thymectomy performed \< 6 months prior to the Screening Visit or have a planned thymectomy during the study
✕ Have any active or untreated malignant thymoma
✕ Additional exclusion criteria are defined in the protocol.